BREAKING: Melanoma Adjuvant Therapy Faces Reimbursement Concerns The lack of definitive overall survival data for adjuvant therapy in stage III melanoma is prompting worries about reimbursement and treatment… The post Melanoma Adjuvant Therapy: OS Data Gaps Explained appeared first on NewsyList. Source link
TOPLINE: Adding radium-223 dichloride (Ra223) to metastasis-directed stereotactic ablative radiotherapy (SABR) did not improve progression-free survival compared with SABR alone in men with bone-only oligometastatic castration-sensitive prostate cancer, according to a phase 2 trial. However, the authors identified two potential prognostic biomarkers — high-risk DNA mutations and T-cell receptor repertoire diversity — to predict progression-free … Read more
TOPLINE: In a multicenter cohort study of 575 South Korean patients with BRCA1 or BRCA2 pathogenic variants, breast-conserving treatment demonstrated comparable oncologic outcomes to mastectomy over a median follow-up of 8.3 years. After propensity score matching, no significant differences between the two surgical approaches were found in terms of locoregional recurrence, distant recurrence, and overall … Read more
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ursula A. Matulonis, MD: Hello. I’m Dr Ursula Matulonis. Welcome to season 2 of the Medscape InDiscussion Endometrial Cancer podcast series. I am honored to have as … Read more
BOSTON — Key DNA and chromosomal and immune cell changes in early-stage lung adenocarcinoma show significant associations with outcomes, representing potentially important early predictors to guide management of the increasingly prevalent, deadly disease, according to the results of a new study. “We found that DNA ploidy and chromosomal structure predict early recurrence in lung adenocarcinoma, … Read more
CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at least 6 months of anticoagulant treatment after a clot, and results in a lower rate of clinically relevant bleeding, the API-CAT trial shows. “Our results indicate … Read more
New findings on radiation plus adjuvant chemotherapy in patients with intermediate-risk cervical cancer seem to spell the end for the dual therapy in this group. Results from a phase 3 clinical trial of 316 women who’d had radical hysterectomies found that adjuvant chemotherapy as treatment for their early-stage, intermediate-risk cervical carcinoma did not improve outcomes … Read more
Key Takeaways For men with genitourinary malignancies, such as prostate cancer, examining the external genital area is essential. While this may seem routine, it remains a crucial recommendation, as illustrated by the case of a patient reported by Portuguese physicians led by José Laert from the Department of Radiology, Hospital CUF Tejo, Lisbon, Portugal. The … Read more
TOPLINE: In patients with ERBB2-positive metastatic breast cancer (ERBB2+ MBC) and brain metastasis, more than half of deaths were due to central nervous system (CNS)–related causes; however, patients with CNS-only metastasis have significantly longer overall survival than those with both CNS and extracranial metastasis. METHODOLOGY: About one third of patients with ERBB2+ MBC develop brain … Read more
The treatment landscape for melanoma saw significant advancements in 2024, as highlighted by Elisa Funck-Brentano, MD, PhD, from Ambroise-Paré Hospital in Paris, France, during her presentation at the 2024 Dermatology Days of Paris conference in Paris. Checkpoint Inhibitors in Neoadjuvant Therapy The standard approach for treating resectable stage III melanoma with locoregional metastases has traditionally … Read more